Science behind Nobel winners spawned one of the biggest marketing duels in pharma history
A timeline of key moments in the development of checkpoint inhibitors
7 drugmakers to watch on Q3 earnings
H Bristol-Myers επενδύει 12 εκατ. στην Compugen για κλινική έρευνα
Top Pharma News of the Week
Sixth-to-market Sanofi scores niche nod for PD-1 player—and blockbuster wannabe—Libtayo
Why Does Immunotherapy Cost So Much?
Nobel Prize in Medicine Awarded to Checkpoint Inhibitor Pioneers
The top 10 drugmakers of 2024
Predicting response to immunotherapy
Pfizer and Merck KGaA are one step closer to a brand-new market for their immuno-oncology drug Bavencio. The companies reported winning data in a kidney cancer trial, setting them up … Continue Reading Can Pfizer and Merck KGaA parlay Bavencio combo data into a kidney cancer win?
Pfizer, Merck Combination Therapy Shows Significant Improvement in Phase III
Roche’s Tecentriq hits a lung cancer slowdown in its bid to challenge Merck
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. Cannabinoid Drug for Pancreatic Cancer Researchers with Queen Mary University of London … Continue Reading Cannabidiol and Pancreatic Cancer, Metformin, Thalidomide and More
Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer Bristol-Myers Squibb Company and Tsinghua University have entered into a collaboration to discover … Continue Reading Top Pharma News of the Week
In the field of immuno-oncology, the two dominant players are Merck & Company, with Keytruda and Bristol-Myers Squibb Company with Opdivo. PD-1 and PD-L1 are proteins found on cancer cells that allow them … Continue Reading Merck Takes Lead from Bristol-Myers Squibb for PD-1/PD-L1